Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Marvel Biosciences Corp V.MRVL

Alternate Symbol(s):  MBCOF

Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.


TSXV:MRVL - Post by User

Post by Whalewatcher1on Jan 17, 2025 12:29pm
18 Views
Post# 36409122

Thoughts on announced offering?

Thoughts on announced offering? I was just shown this deal, anyone with any thoughts on it? Is it tied to Algernon pharma, that’s been huge loss and mess and loss of investment. Marvel appears to be running the same “repurposing” story that Algernon ran and now looks close to being dead.
 
This offering is to pay $1M of debt, $360k deposit on a safety clinical trial and fund salaries.  Phase 1 safety studies don’t move the share price needle. They’ll still have $700k in debt. I don’t get it, if they hit the $1.9M min offering size there wont be any science completed. They are likely $5M+ away from any efficacy data in patients with disease.  Why would anyone invest in this, maybe i'm just missing something important? Would be great to get a discussion going 
 
<< Previous
Bullboard Posts